Effects of atorvastatin on MMPs and vWF in peripheral blood lymphocytes in patients of early chronic kidney disease with carotid artery plaque
Qu Zhongsen1, Pan Yongchao2, Zhang Qingde3
1Department of Rehabilitation, 2Department of Neurology, the Sixth People′s Hospital Affiliated to Shanghai Health Medical College, Shanghai 201306, China; 3Department of Urology, Heze Municipal Hospital, Heze 274031, China
Abstract：ObjectiveTo explore the effects of atorvastatin on matrix metalloproteinase (MMPs) and von Willebrand factor (vWF) in peripheral blood lymphocytes in patients of early chronic kidney disease (CKD) with carotid artery plaque. MethodsFrom January to October 2017, 143 patients with stage 1-2 CKD and carotid artery plaque who visited the Kidney Department of the East Hospital of Shanghai Sixth People′s Hospital and Heze Municipal Hospital were selected. According to the random number table method, they were divided into the CKD group (n=76) and the treatment group (n=67), and 50 healthy people with normal physical examination in the corresponding period were selected as the control group. The treatment group was treated with atorvastatin for oral administration. After 6 months of treatment, blood lipid level and carotid intimamedia thickness (IMT) of the 3 groups were compared, and the changes of MMP-2, MMP-9 and vWF levels of peripheral blood lymphocytes in the 3 groups were compared after 1, 2, 3 and 6 months of treatment. ResultsCompared to the control group, after 6 months of treatment, the triglycerides levels ［(1.42±0.40)mmol/L, (3.58±0.78)mmol/L, (1.78±0.46)mmol/L］, total cholesterol levels ［(4.56±0.78)mmol/L, (6.88±1.39)mmol/L, (5.16±1.14)mmol/L］, IMT levels ［(0.78±0.23)mm, (1.56±0.43)mm, (1.06±0.22)mm］ and peripheral blood lymphocytes of MMP-9 levels ［（124.10±42.96）μg/L，（232.82±90.16）μg/L，（158.57±57.14）μg/L］, MMP-2 levels ［（141.09±44.98）μg/L，（262.82±110.98）μg/L，（154.48±56.86）μg/L］ and vWF levels ［（111.68±42.29）μg/L, （276.82±111.68）μg/L，（142.32±46.44）μg/L］ in the CKD group and treatment group were significantly increased, with statistically significant differences (F=5.90, 4.28, 3.45, 11.34, 12.45, 12.35, all P＜0.05). The levels of triglyceride, total cholesterol, IMT, MMP-9, MMP-2 and vWF levels in the treatment group were lower than those in the CKD group, all the differences were statistically significant (t=4.21, 1.22, 5.13, 4.90, 5.90, 10.00, all P＜0.05). ConclusionsIn early CKD patients with carotid artery plaque, atorvastatin may play a role in stabilizing plaques by reducing MMP-2, MMP-9 and vWF levels in peripheral blood lymphocytes.
曲忠森 潘永超 张清德. 阿托伐他汀对早期慢性肾脏病伴颈动脉斑块患者外周血淋巴细胞基质金属蛋白酶血管性假血友病因子的作用[J]. 中华诊断学电子杂志, 2020, 8(4): 231-236.
Qu Zhongsen1, Pan Yongchao2, Zhang Qingde3. Effects of atorvastatin on MMPs and vWF in peripheral blood lymphocytes in patients of early chronic kidney disease with carotid artery plaque. zhzdx, 2020, 8(4): 231-236.
